Science Corporation CEO Max Hodak discusses the future of technology and brain-computer interfaces at TechCrunch Disrupt 2026, highlighting advancements in their biohybrid technology and its potential applications.

US · 2026-09-16

1. Step 1 · The triggerScience Corporation's high-profile showcase of biohybrid BCI technology at TechCrunch Disrupt 2026 raises its visibility among investors and potential partners.
2. Step 2 · Knock-onIncreased investor and partner attention accelerates Science Corp's access to capital and commercial collaborations, boosting its pace of product development and deployment.
3. Step 3 · Reaches youThe momentum in BCI adoption creates new partnership and supply opportunities for US medtech SMEs, while raising competitive pressure on established players like Neuralink.

The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.

Source: TechCrunch

This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.